Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,963 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,963 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Open enrollment, early-phase tilt

Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.

423
recruiting participants now
34%
of trials open to enrollment
120
in Phase 3-4 (later-stage)
98
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Open and recent trials

1,251 total, page 17 of 26

COMPLETED NA 357 participants

Four Conversations RCT

Duke University

NCT02944344

COMPLETED 351 participants

Joint Pain and Medication Adherence in Postmenopausal Women Receiving Aromatase Inhibitors

Vanderbilt University Medical Center

NCT00954564

COMPLETED NA 340 participants

Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting

Fox Chase Cancer Center

NCT01440855

COMPLETED NA 325 participants

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

Alliance for Clinical Trials in Oncology

NCT00417040

COMPLETED NA 323 participants

Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening

Johns Hopkins Bloomberg School of Public Health

NCT05665660

COMPLETED 322 participants

Screening in Myocardial Perfusion Patients

Mayo Clinic

NCT00943241

COMPLETED Phase 2 321 participants

Soy Protein and Breast Cancer Risk Reduction

The University of Texas Medical Branch, Galveston

NCT00204477

COMPLETED Phase 2 320 participants

Compare Outcomes Between Two Acellular Dermal Matrices

Washington University School of Medicine

NCT02891759

COMPLETED 316 participants

Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer

Mayo Clinic

NCT00897208

COMPLETED Phase 2 309 participants

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Novartis Pharmaceuticals

NCT01783444

COMPLETED Phase 3 308 participants

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Sandoz

NCT01516736

COMPLETED NA 301 participants

OPTimizing Treatment Focused Genetic Testing IN Cancer

Dana-Farber Cancer Institute

NCT04066361

COMPLETED Phase 3 300 participants

Physical Activity Promotion in Cancer Follow-Up Care

The Miriam Hospital

NCT00230711

COMPLETED NA 300 participants

Redes III Patient Navigator Qol Study

The University of Texas Health Science Center at San Antonio

NCT02275754

COMPLETED Phase 3 300 participants

Vitamin D and Breast Cancer Biomarkers in Female Patients

Alliance for Clinical Trials in Oncology

NCT01224678

COMPLETED Phase 3 299 participants

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

SWOG Cancer Research Network

NCT01598298

COMPLETED 298 participants

A Multi-Reader Multi-Case Pivotal Trial

Fujifilm Medical Systems USA

NCT02692209

COMPLETED Phase 2 288 participants

Acupressure for Persistent Cancer Related Fatigue

University of Michigan

NCT01281904

COMPLETED Phase 3 280 participants

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Fred Hutchinson Cancer Center

NCT00003972

COMPLETED 276 participants

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Genentech

NCT01598597

COMPLETED NA 276 participants

Decision Support for BRCA Testing in Ethnically Diverse Women

Columbia University

NCT03470402

COMPLETED Phase 3 273 participants

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

M.D. Anderson Cancer Center

NCT00336791

COMPLETED 270 participants

Evaluation of BIS for Quantification of Lymphedema

Massachusetts General Hospital

NCT01544335

COMPLETED 266 participants

Investigating the Impact of Tamoxifen Therapy on Ovarian Aging

University of California, San Francisco

NCT01384526

COMPLETED 262 participants

Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT

Lunit

NCT05716958

COMPLETED Phase 3 250 participants

Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer

Dana-Farber Cancer Institute

NCT00146549

COMPLETED Phase 3 249 participants

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

International Breast Cancer Research Foundation

NCT00293540

COMPLETED 246 participants

Biomarkers in Blood Samples From Older Breast Cancer Survivors

UNC Lineberger Comprehensive Cancer Center

NCT01138345

COMPLETED Phase 3 245 participants

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Georgetown University

NCT00685256

COMPLETED 240 participants

Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women

University of Arizona

NCT01817231

COMPLETED 239 participants

Neuropathic Pain in Survivors of Breast Cancer

M.D. Anderson Cancer Center

NCT00535067

COMPLETED Phase 1 229 participants

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma

NCT02632448

COMPLETED Phase 3 226 participants

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

Alliance for Clinical Trials in Oncology

NCT00046891

COMPLETED Phase 4 219 participants

Quantitative Subharmonic Breast Imaging

Thomas Jefferson University

NCT01490892

COMPLETED Phase 2 215 participants

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

SWOG Cancer Research Network

NCT00856492

COMPLETED Phase 3 213 participants

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Alliance for Clinical Trials in Oncology

NCT00377156

COMPLETED NA 213 participants

Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy

Duke University

NCT00734838

COMPLETED Phase 2 209 participants

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT00005798

COMPLETED 206 participants

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

NanoString Technologies

NCT02625935

COMPLETED 200 participants

Infrared Imaging (Breast Scan IR) for Early Breast Cancer Detection

Weill Medical College of Cornell University

NCT00195026

COMPLETED Phase 2 200 participants

Delayed-Immediate Breast Reconstruction

M.D. Anderson Cancer Center

NCT00473122

COMPLETED Phase 1 200 participants

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

InventisBio Co.

NCT03471663

COMPLETED NA 199 participants

To Enhance Breast Cancer Survivorship of Asian Americans

Emory University

NCT02803593

COMPLETED NA 194 participants

Southeast Asian Women's Health Project

Ohio State University

NCT04086771

COMPLETED Phase 2 187 participants

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

Eli Lilly and Company

NCT00320541

COMPLETED 185 participants

Pre-biopsy With Dynamic Acquisitions

Mayo Clinic

NCT00943644

COMPLETED NA 183 participants

Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions

University of Michigan

NCT00721435

COMPLETED 183 participants

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

Case Comprehensive Cancer Center

NCT00666913

COMPLETED NA 183 participants

Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer

Abramson Cancer Center at Penn Medicine

NCT00892515

COMPLETED 180 participants

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

SWOG Cancer Research Network

NCT00002900

← Previous Page 17 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Breast Cancer right now

423 recruiting of 1,251 indexed (34% open).

Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Breast Cancer?

PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Breast Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.